Healthcare·1 min read·Author: Financial Times
Samsung Biologics Plant 5 construction hits key milestone
Capacity expansion continues as global pharma clients lock in long-term biologics manufacturing slots.
Updated: Jul 11, 2026, 04:45 AM GMT-3
Koreabw AI
Capacity expansion continues as global pharma clients lock in long-term biologics manufacturing slots.
Samsung Biologics said demand for large-scale mammalian manufacturing remains robust.
The Songdo campus is becoming one of the world's densest biologics production hubs.
Related companies
Where it matters
TagsSamsung BiologicsCDMObiomanufacturing
Related coverage
Global Businesstheglobeandmail.com
Samsung Biologics Nears Control of PolyPeptide After Strong Tender Uptake
Healthcarebiz.heraldcorp.com
Celltrion Launches Omryklo in the US, Expanding Allergy Treatment Portfolio
Healthcarerttnews.com
Celltrion Launches OMLYCLO, First Interchangeable Omalizumab Biosimilar in U.S.
Healthcarebiz.chosun.com